Novel CAR-T Cell Therapy Produces Early and Deep Responses in Certain Patients With Multiple Myeloma
Last Updated: Friday, June 25, 2021
Treatment with a single infusion of the novel CAR-T cell therapy ciltacabtagene autoleucel (cilta-cel) induced early and deep responses in a group of patients with relapsed/refractory multiple myeloma, according to results of a phase II study presented during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
Advertisement
News & Literature Highlights